Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial
Vicente Navarro‐López, Adriana Hernández-Belmonte, María Isabel Pérez Soto, Maikel Ayo-González, Guillermo Losa-Rodríguez, Esther Ros-Sánchez, Maravillas Martínez-Gabarrón, Pedro Sánchez-Pellicer, Juan Agüera-Santos, Eva Núñez-Delegido, Beatriz Ruzafa-Costas, José Antonio Picó-Monllor, Laura Navarro-Moratalla
Abstract
CECT 30579, administered for 30 days, on the evolution of COVID-19 patients. Analysis of the digestive symptoms at the end of the follow up shows a benefit of the probiotic in the number of patients without pyrosis (100% vs 33.3%; p 0.05) and without abdominal pain (100% vs 62.5%; p 0.04). Results also show a better evolution when evaluating the difference in the overall number of patients without non-digestive symptoms at the end of the follow-up (41.7%, vs 13%; p 0.06). The percentage of improvement in the digestive symptoms (65% vs 88%; p value 0.06) and the global symptoms (digestive and non-digestive) (88.6% vs 70.8%; p value 0.03) is higher in the probiotic group. The probiotic was well tolerated with no relevant side effects and high adherence among patients. In conclusion, this coadjutant treatment seems to be promising, although results should be confirmed in new studies with higher number of patients.